Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development.

EVT 302, a reversible and highly selective inhibitor of MAO-B in development for smoking cessation, was investigated in an ascending dose study with repeated daily dosing in a total of 84 healthy young and elderly subjects. Healthy young male subjects were treated with EVT 302 2.5, 5, 15 mg, or placebo for two weeks, and healthy elderly male and female subjects were treated with EVT 302 2.5 mg, 10 mg, or placebo for four weeks. Each treatment was received by 12 young and/or elderly subjects as appropriate. The highest dose levels exceed the expected maximum therapeutic dose planned to be used in further clinical trials. For the treatment period and part of the subsequent washout phase the subjects were confined to the clinical research unit.

The study was aimed at investigating safety/tolerability, pharmacokinetics, and pharmacodynamics (inhibition of MAO-B in platelets) during prolonged dosing with EVT 302 as compared to placebo. The study was conducted and successfully completed as planned per protocol. The results are still blinded and will become available as final evaluated data over the next two months.

The preliminary data indicate that EVT 302 was well tolerated in young and elderly subjects up to the highest dose levels tested in this study. Adverse events (AEs) classified as possibly treatment related were transient and mostly of mild intensity; only very few moderate AEs were reported. No severe or serious AEs occurred.

No clinically relevant changes in lab values of haematology or clinical chemistry were noted. In particular, there were no changes in liver function test
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 21, 2014 The ... the inorganic refrigerants market in Americas with analysis ... TOC of the Americas Inorganic Refrigerants Market report, ... provided. This also provides a glimpse of the ... is supported by various tables and figures. ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... ... to experts, policymakers, and celebrities on issues that affect us all. Viewers any where ... or issues raised in our comedy and shows. Over 60 controversial episodes and hundreds ... ...
... , June 29 The Clinical Laboratory Management Association ... association,s annual meeting, with a 30% increase in attendance and more ... , , ... robust educational offerings and a packed Exhibit Hall, the event provided ...
... HONG KONG , June 29 /PRNewswire-Asia-FirstCall/ ... announced that it joined the,Russell Global Index after the market close on ... , , ... which remains in place for one,year, means automatic inclusion in the appropriate ...
Cached Biology Technology:Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics 2Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics 3Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics 4Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics 5Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics 6Clinical Laboratory Management Association's ThinkLab '10 Surpasses Attendance Goals 2China Cord Blood Corporation Joins Russell Global Index 2China Cord Blood Corporation Joins Russell Global Index 3
(Date:10/14/2014)... study published in Cancer Research shows SIRT6—a ... colon cancers—can promote the development of skin cancers by ... survival of sun-damaged skin cells. , Previously considered protective, ... called sirtuins that help regulate genomic stability and prevent ... helps repair DNA damage, which can lead to cancer. ...
(Date:10/14/2014)... leading questions is how to produce enough food to ... Food and Agriculture Organization of the United Nations predicts ... 40 years to feed a growing global population, and ... in food production. Plants—grains, cereals, fruits, vegetables, and ... Current research must tap into our knowledge of how ...
(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Service Weekly PressPac with news from ACS 36 peer-reviewed journals ... the American Chemical Society as the source for this information. ... which is embargoed for 9 A. M., Eastern Time, Jan. ... Seagull blood shows promise for monitoring pollutants ...
... elderly residents and giving them fewer sleeping pills could ... nursing home units published in the January issue of ... by the Karolinska Institutet, Sweden, analysed 2,343 reported falls ... how they related to fall risk assessments and the ...
... have been lost from West Antarctica and the Antarctic peninsula ... University of Bristol and published online this week in Nature ... has been roughly stable, with neither loss nor accumulation over ... of Bristol and colleagues estimated the flux of ice from ...
Cached Biology News:American Chemical Society's weekly PressPac -- Jan. 9, 2008 2American Chemical Society's weekly PressPac -- Jan. 9, 2008 3American Chemical Society's weekly PressPac -- Jan. 9, 2008 4American Chemical Society's weekly PressPac -- Jan. 9, 2008 5American Chemical Society's weekly PressPac -- Jan. 9, 2008 6American Chemical Society's weekly PressPac -- Jan. 9, 2008 7American Chemical Society's weekly PressPac -- Jan. 9, 2008 8American Chemical Society's weekly PressPac -- Jan. 9, 2008 9Selective restraints and reduced medication could reduce nursing home falls says 4-year study 2Antarctic ice loss 2
... Description: ,Kit containing Dermal Fibroblasts ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ... ,Source: Dermis, mouse/BalbC, embryonic day 18.5 ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... Service, We deliversoluble protein or No ... yields the best soluble protein results , ... clone submitted , Powerful results on your ... Solubility Optimization Service (SOS) uses proprietary tools ...
Biology Products: